Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label phase 2 multi-center study of abiraterone and enzalutamide in men with
castration-resistant prostate cancer. Sixteen patients will be enrolled over 18 months.